Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Q&A: Lead Left Interview – Ilan Nissan (<i>The Lead Left</i>)

main

12_19_17 Nissan QA The Lead Left

Q&A: Lead Left Interview – Ilan Nissan (<i>The Lead Left</i>) 

Q&A: Lead Left Interview – Ilan Nissan (The Lead Left)

Related Content

The UK’s Defence Commitment Is Sending Markets a Signal

Luxembourg Tax Alert — Advocate General Recommends Dismissal of Commission Action Concerning Luxembourg's Application of the ATAD Interest Limitation Rules to Certain Securitisation Vehicles

How Generative AI Is Changing the Game for Deal Lawyers (Law.com)

FDIC Approves Deposit Insurance Applications for ILCs Proposing Specialty Business Models

Expanding Corporate Criminal Liability in the UK: Key Impacts and Considerations for Organisations and Investors

SEC Raises Advisers Act “Qualified Client” Dollar-Based Thresholds

Getting Traction in European Defence

Access to UK Company Privileged Documents by Former Directors

Goodwin Pharma Services Symposium

Goodwin Advises Demea Agro on the Sale of Polaris to Motion Equity Partners

Goodwin Advises Mission BioCapital on Securing Eligibility for $44.5 Million Non-Dilutive Funding Through AMED Program

Goodwin Advises Catalent on $4.7 Billion Debt Refinancing

Goodwin Earns Top Spot for Global M&A in H1 2026 League Tables

AstraZeneca May Keep Chasing Transformative M&A or Merger After Abandoned BMS Deal (Mergermarket)

Goodwin Advises Maguar Capital on the Financing of its Partnership With Schlafender Hase

Goodwin Advises Thoma Bravo on $4 Billion Acquisition of Accelerant

Private Equity

Mergers & Acquisitions